GSK plc
GSK
$51.84
-$0.53-1.01%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.26% | 10.54% | 7.26% | 1.39% | 3.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.26% | 10.54% | 7.26% | 1.39% | 3.93% |
| Cost of Revenue | 7.12% | -0.34% | 11.18% | -0.26% | 11.92% |
| Gross Profit | 11.69% | 14.99% | 5.87% | 1.97% | 0.66% |
| SG&A Expenses | 5.63% | -40.53% | -5.54% | -1.44% | 4.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -475.59% | -177.22% | -80.90% | 43.95% | 130.93% |
| Total Operating Expenses | 2.00% | -22.90% | 3.29% | 2.23% | 15.85% |
| Operating Income | 68.87% | 378.79% | 17.87% | -0.46% | -39.91% |
| Income Before Tax | 75.24% | 3,876.38% | 33.66% | 54.52% | 53.15% |
| Income Tax Expenses | 273.53% | 32,429.43% | 33.61% | 21.80% | 436.43% |
| Earnings from Continuing Operations | 50.70% | 3,317.84% | 33.66% | 62.81% | 29.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.62% | -10.36% | -64.09% | -320.00% | -86.87% |
| Net Income | 59.54% | 3,696.29% | 30.27% | 54.21% | 21.95% |
| EBIT | 68.87% | 378.79% | 17.87% | -0.46% | -39.91% |
| EBITDA | 51.03% | 144.64% | 34.87% | 9.03% | -2.29% |
| EPS Basic | 62.05% | 3,737.30% | 30.76% | 53.47% | 21.18% |
| Normalized Basic EPS | 94.23% | 728.26% | 14.78% | -8.11% | -48.59% |
| EPS Diluted | 60.64% | 3,678.92% | 30.43% | 53.68% | 20.94% |
| Normalized Diluted EPS | 94.07% | 726.47% | 14.67% | -8.20% | -48.64% |
| Average Basic Shares Outstanding | -1.52% | -1.13% | -0.39% | 0.47% | 0.62% |
| Average Diluted Shares Outstanding | -1.42% | -0.94% | -0.29% | 0.58% | 0.70% |
| Dividend Per Share | 16.84% | 10.50% | 12.95% | 5.94% | 3.12% |
| Payout Ratio | -0.31% | 1.03% | -0.18% | -0.31% | -0.09% |